Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxaliplatin + Fluorouracil + Leucovorin + Bevacizumab
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This regimen is a combination chemotherapy protocol used primarily for the treatment of metastatic colorectal cancer. It consists of four drugs: oxaliplatin (a platinum-based cytotoxic agent), fluorouracil (5-FU, an antimetabolite that inhibits DNA synthesis), leucovorin (folinic acid, which enhances the effect of fluorouracil), and bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor A to inhibit angiogenesis). The combination works by interfering with cancer cell division and growth while also blocking the formation of new blood vessels that supply tumors. This regimen is typically administered intravenously in cycles every two weeks and has been shown to improve survival outcomes in patients with metastatic colorectal cancer[1][4][5][6][7].
- Brand names
- None
- Other names
- FOLFOX-bevacizumabmFOLFOX6+BEVAGIFFOXB
02
Targets
Beyond the preview
Go deeper on Oxaliplatin + Fluorouracil + Leucovorin + Bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxaliplatin + Fluorouracil + Leucovorin + Bevacizumab.